Cost-effectiveness of buprenorphine–naloxone versus extended-release naltrexone to prevent opioid relapse

Sean M. Murphy, Kathryn E. McCollister, Jared A. Leff, Xuan Yang, Philip J. Jeng, Joshua D. Lee, Edward V. Nunes, Patricia Novo, John Rotrosen, Bruce R. Schackman

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Cost-effectiveness of buprenorphine–naloxone versus extended-release naltrexone to prevent opioid relapse'. Together they form a unique fingerprint.

Medicine & Life Sciences